Global Laryngeal Cancer Therapeutics Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Laryngeal Cancer Therapeutics Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Laryngeal Cancer Therapeutics Market

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period
2022 –2029
Diagram Market Size (Base Year)
USD 3.80 Billion
Diagram Market Size (Forecast Year)
USD 5.40 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Laryngeal Cancer Therapeutics Market, By Product Type (Biologics, Small Molecules), Treatment Type (ImmunotherapyChemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Laryngeal Cancer Therapeutics Market

Laryngeal Cancer Therapeutics Market Analysis and Size

The global laryngeal cancer therapeutics market is expected to witness significant growth during the forecast period. As per the American Cancer Society records, over 90% of the patients with stage 1 glottis cancer survive for a phase of more than five years. This inspiring market growth can contribute to advancing the healthcare industry and the therapeutics sector for cancer treatments. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global laryngeal cancer therapeutics market in the forecast period 2022-2029. The expected CAGR of global laryngeal cancer therapeutics market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 3.8 billion in 2021, and it would grow upto USD 5.40 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Laryngeal cancer is a rare type of rare cancer in which malignant cells grow in the voice box or the larynx. Laryngeal cancer mostly begins in the glottis area of the larynx. Most laryngeal cancers begin as the flat, scale-like squamous cells that line the inner walls of the larynx. Symptoms include sore throat, hoarseness, persistent cough, persistent bad breath, difficulty or pain in swallowing, difficulty or noisy breathing, significant weight loss, and constant ear pain. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period

Laryngeal Cancer Therapeutics Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Biologics, Small Molecules), Treatment Type (Immunotherapy, Chemotherapy, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany)

Market Opportunities

  • Increased Incidence of Cigarette Smoking
  • Rising Healthcare Awareness
  • Rising Prevalence of Laryngeal Cancer

Global Laryngeal Cancer Therapeutics Market Dynamics

Drivers

  • Higher Demand of Precision Medicine

Precision medicine are excessively applied when cancer therapeutics is involved. The popularity of precision medicine and its specificity towards the cancer treatment of every patient being based on type of cancer combined with genetic information from the patient improves the success rates of the procedure. This boost the market growth.

  • Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global laryngeal cancer therapeutics market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

  • Increased Incidence of Cigarette Smoking

Cigarette smoking is one of the major reasons for emphysema. According to the American Lung Association (ALA) reports, cigarette smoking alone caused approximately 85–90% of all chronic obstructive pulmonary diseases (COPDs). It leads to the weakening of lungs. Hence, this creates more opportunities in the market.

  • Rising Healthcare Awareness

Health awareness amongst the population are rising, which results in the prediction of drugs boost the market growth. The innovative launches in medications for treating laryngeal cancer are expected to boost the market simultaneously. Different researchers are investing in launching the drugs that benefit the market.This creates more opportunities in the market.

  • Rising Prevalence of Laryngeal Cancer

As per the records of the American Cancer Society, the occurrence of laryngeal cancer is about 3.6 people in 100,000 population per year in U.S. This projected to over 13,365 new cases of laryngeal cancer in 2017. The new cases of laryngeal cancer in 2019 was projected to be over 12,415 cases.

Restraints/Challenges

  • Inclination of Alternative Treatments

The preference for alternative treatment options will obstruct the growth of the market. The majority of patients with laryngeal cancer prefer surgery due to its strong efficacy and faster recovery process. Additionally, advances in healthcare infrastructure have led to the beginning of new surgical methods that promise low risk. Thus, the growing advancements in treatment methods are expected to restrict the growth of the global laryngeal cancer therapeutics market.

  • High Cost

The huge expenditure of the treatment methods hampers the market growth. The different treatment methods such as precision medicine, chemotherapy, immunotherapy and many others require increased cost and the patients' longer hospital stays which in turn requires higher cost. Thus, it restricts the growth of the market.

This global laryngeal cancer therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global laryngeal cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Laryngeal Cancer Therapeutics Market

During the COVID-19 pandemic, routine health services were restricted, and surgeries were cancelled except for the emergency and severe oncological cases . These changes made it tough for cancer patients to reach healthcare facilities leading to delays in scheduled appointments and diagnosis of the patients suffering from laryngeal or oropharyngeal cancer. The time between cancer diagnosis and surgery might rise during the pandemic because of the lack of the medical and health care providers. However, in the post-pandemic era, an effective appointment system, telemedicine, or higher priority for cancer patients declined the delays in laryngeal cancer patients. Thus, the market is seemed to grow in the current era.

Global Laryngeal Cancer Therapeutics Market Scope

The global laryngeal cancer therapeutics market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Biologics
  • Small Molecules

Treatment Type

  • Chemotherapy
  • Immunotherapy
  • Others

Route of Administration

End-Users

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Laryngeal Cancer Therapeutics Market Regional Analysis/Insights

The global laryngeal cancer therapeutics market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global laryngeal cancer therapeutics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the increase prevalence of laryngeal cancer and advanced healthcare facilities

Asia-Pacific dominates the market due to the rising cases of cardiovascular diseases and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Laryngeal Cancer Therapeutics Market Share Analysis

The global laryngeal cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global laryngeal cancer therapeutics market.

Key players operating in the global laryngeal cancer therapeutics market include:

  • Johnson & Johnson Private Limited (U.S.)
  • Cipla Inc. (U.S.)
  • Abbott (U.S.)
  • AbbVie Inc. (U.S.)
  • Merck KGaA (Germany)
  • Bausch Health Companies Inc. (Canada)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Laryngeal Cancer Therapeutics Market is projected to grow at a CAGR of 4.50% during the forecast period by 2029.
The future market value of the Laryngeal Cancer Therapeutics Market is expected to reach USD 5.40 billion by 2029.
The major players in the Laryngeal Cancer Therapeutics Market are Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Merck KGaA (Germany), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), etc.
The countries covered in the Laryngeal Cancer Therapeutics Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, etc.